Excluding sales of PPE and COVID-19 related products, internal sales growth in local currencies was 2.4%. Global Dental consumable merchandise internal sales decreased by 2.2% in local currencies.The 0.3% internal sales decrease in local currencies included a 1.1% decrease in North America and 1.0% growth internationally. Internally generated sales in local currencies decreased 0.3%, with 0.7% growth from acquisitions and a 3.5% decrease related to foreign currency exchange. Global Dental sales for the second quarter of 2022 of $1.9 billion decreased 3.1% compared with the prior-year period.(See Exhibit B for a reconciliation of GAAP net income and diluted EPS to non-GAAP net income and diluted EPS.) of $157 million, or $1.11 per diluted share. of $156 million, or $1.10 per diluted share, and second-quarter 2021 non-GAAP net income attributable to Henry Schein, Inc. for the second quarter of 2022 was $160 million, or $1.16 per diluted share, compared with second-quarter 2021 GAAP net income attributable to Henry Schein, Inc. GAAP net income attributable to Henry Schein, Inc.(See Exhibit A for details of sales growth.) Second-quarter internal sales growth in local currencies excluding sales of PPE and COVID-19 related products was 6.7% compared with the prior year. The 2.1% increase included 2.4% internal growth in local currencies, 2.1% growth from acquisitions, and a 2.4% decrease related to foreign currency exchange. Total net sales for the quarter ended June 25, 2022, were $3.0 billion, up 2.1% compared with the second quarter of 2021.Henry Schein One sales growth accelerated compared with prior-year growth, and we are seeing healthy demand from our national DSO accounts for these solutions,” concluded Mr. “We are pleased with the good growth in our Technology & Value-Added Services business where, once again, North America and International sales increased by double-digit percentages. Patient traffic was bolstered by a high number of visits for seasonal influenza. During the second quarter, we had strong sales of point-of-care diagnostic tests including flu test kits, as well as generic pharmaceuticals and equipment. “Our Global Medical business had another excellent quarter with double-digit internal sales growth in local currencies when excluding PPE and COVID-19 related products. Consumable merchandise internal sales growth in local currencies excluding personal protective equipment (PPE) and COVID-19 related products was impacted by an increase in patient appointment cancellations and staff shortages, which we believe were related to COVID-19 infections. “Our Global Dental business once again was driven by strong equipment sales as dentists continued to invest in their practices. dollar and declining demand for COVID-19 test kits. While we are maintaining our full-year 2022 diluted EPS guidance range of $4.75 to $4.91, we are adjusting our expectations for full-year sales growth to reflect changes including a continued strengthening of the U.S. “Our solid operational execution this quarter and our results demonstrate the strength of our business. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “We are pleased to report record second-quarter financial results that reflect good underlying momentum in the business and execution of our strategy,” said Stanley M. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today reported record second-quarter financial results. Affirms full-year 2022 GAAP diluted EPS guidance range of $4.75 to $4.91, reflecting growth of 7% to 10% over full-year 2021 GAAP diluted EPS and growth of 5% to 9% over full-year 2021 non-GAAP diluted EPS.
GAAP diluted EPS of $1.16 compared with second-quarter 2021 GAAP diluted EPS of $1.10 and second-quarter 2021 non-GAAP diluted EPS of $1.11.Second-quarter net sales of $3.0 billion up 2.1% compared with second-quarter 2021 internal sales up 6.7% in local currencies when excluding sales of PPE and other COVID-19 related products.
0 kommentar(er)
